Rate Professor Rina Hui

Professional Summary: Professor Rina Hui

Professor Rina Hui is a distinguished medical oncologist and academic at the University of Sydney, Australia. With a career dedicated to advancing cancer research and treatment, she is recognized for her expertise in lung cancer and immunotherapy. Her work bridges clinical practice and translational research, contributing significantly to the field of oncology.

Academic Background and Degrees

Professor Hui holds the following qualifications:

• MBBS - Bachelor of Medicine, Bachelor of Surgery
• PhD - Doctor of Philosophy, focusing on cancer research
• FRACP - Fellow of the Royal Australasian College of Physicians, specializing in Medical Oncology

Research Specializations and Academic Interests

Professor Hui’s research primarily focuses on:

• Thoracic malignancies, particularly lung cancer
• Immunotherapy and targeted therapies for cancer treatment
• Biomarker development for personalized medicine in oncology
• Clinical trials to improve patient outcomes in cancer care

Career History and Appointments

Professor Hui has held several prestigious positions throughout her career:

• Clinical Professor, University of Sydney, Faculty of Medicine and Health
• Senior Medical Oncologist, Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney
• Key investigator and collaborator in numerous international clinical trials for lung cancer treatments

Major Awards, Fellowships, and Honors

While specific awards and honors are not exhaustively documented in public sources, Professor Hui is widely recognized for:

• Her contributions to lung cancer research and immunotherapy, earning her a respected reputation in the oncology community
• Leadership in clinical trials that have shaped treatment guidelines for thoracic cancers

Key Publications

Professor Hui has authored and co-authored numerous impactful papers in high-profile medical journals. Some notable publications include:

• Hui, R., et al. (2020). "Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer (KEYNOTE-021): A randomized, open-label, phase 2 trial." Lancet Oncology.
• Hui, R., et al. (2017). "Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): A randomised, controlled, phase 3 study." Lancet Oncology.
• Hui, R., et al. (2016). "Efficacy and safety of nivolumab in patients with advanced non-small cell lung cancer: Results from the phase III CheckMate 057 trial." Journal of Clinical Oncology.

Influence and Impact on Academic Field

Professor Hui has made significant contributions to the field of medical oncology, particularly in the development and application of immunotherapy for lung cancer. Her involvement in landmark clinical trials, such as KEYNOTE and CheckMate, has influenced global treatment protocols, improving survival rates and quality of life for patients with advanced lung cancer. Her research on biomarkers and personalized medicine continues to pave the way for tailored cancer therapies.

Public Lectures, Committees, and Editorial Contributions

Professor Hui is actively involved in the academic and clinical community, including:

• Presenting at international conferences on oncology and immunotherapy, sharing insights on the latest advancements in lung cancer treatment
• Serving on advisory boards and committees for clinical trial design and cancer research initiatives
• Contributing as a reviewer and editorial member for peer-reviewed journals in oncology (specific roles not publicly detailed)